<p>Metagenomi, Inc.（纳斯达克代码：MGX - 获取免费报告）目前获得了五位分析师的平均推荐评级为 “适度买入”，MarketBeat 报道称。其中一位分析师给予该股票卖出评级，三位分析师给予买入评级，另一位分析师则给予强烈买入评级。在过去一年中，发布报告的券商对该股票的平均一年目标价为 10.00 美元。</p>
<p>几位研究分析师对该股票发表了看法。HC Wainwright 在 8 月 19 日的研究报告中重申了 “买入” 评级，并对 Metagenomi 的股票设定了 7.00 美元的目标价。Chardan Capital 将 Metagenomi 的目标价从 12.00 美元下调至 11.00 美元，并在 8 月 15 日的报告中给予该公司 “买入” 评级。Zacks Research 在周五的研究报告中将 Metagenomi 的评级从 “持有” 上调至 “强烈买入”。富国银行在 8 月 14 日的研究报告中将 Metagenomi 的目标价从 16.00 美元下调至 12.00 美元，并对该股票给予 “超配” 评级。最后，Weiss Ratings 在 10 月 8 日的报告中重申了对 Metagenomi 股票的 “卖出（d-）” 评级。</p>
<p><strong>查看我们对 MGX 的最新分析</strong></p>
<h2>机构资金流入和流出</h2>
<p>大型投资者最近调整了对该公司的持股。Vanguard Personalized Indexing Management LLC 在第二季度将其在 Metagenomi 的持股增加了 53.1%。Vanguard Personalized Indexing Management LLC 目前拥有 21,515 股该公司的股票，价值 32,000 美元，此前在此期间购买了 7,458 股。Virtu Financial LLC 在第一季度购买了价值 43,000 美元的 Metagenomi 新股份。纽约梅隆银行在第一季度将其在 Metagenomi 的持股增加了 39.6%。纽约梅隆银行目前拥有 50,387 股该公司的股票，价值 69,000 美元，此前在此期间又收购了 14,296 股。美国银行在第四季度将其在 Metagenomi 的持股增加了 482.9%。美国银行目前拥有 21,113 股该公司的股票，价值 76,000 美元，此前在上个季度又购买了 17,491 股。最后，Nuveen LLC 在第一季度收购了价值约 86,000 美元的 Metagenomi 新股份。</p>
<h2>Metagenomi 股票上涨 9.8%</h2>
<p>纳斯达克：MGX 周二开盘价为 3.35 美元。该股票的 50 日简单移动平均为 2.22 美元，200 日简单移动平均为 1.91 美元。该公司的市值为 1.2573 亿美元，市盈率为-1.42，贝塔值为 0.27。Metagenomi 的一年低点为 1.23 美元，一年高点为 4.92 美元。</p>
<p>Metagenomi（纳斯达克：MGX - 获取免费报告）最近一次公布财报是在 8 月 12 日。该公司报告季度每股收益为（0.54 美元），超出市场共识预期的（0.68 美元）0.14 美元。该公司在该季度的收入为 851 万美元，而分析师预期为 772 万美元。Metagenomi 的净利润率为-257.99%，股本回报率为-37.84%。股票分析师预测 Metagenomi 本年度每股收益将为-2.46 美元。</p>
<h2>Metagenomi 公司简介</h2>
<p>（获取免费报告）</p>
<p>Metagenomi, Inc. 是一家基因治疗公司，专注于利用元基因组学衍生的基因组编辑工具箱为患者开发治疗方案。该公司的基因组编辑工具箱包括可编程核酸酶、碱基编辑器以及 RNA 和 DNA 介导的整合系统，如原始编辑系统和成簇规律间隔短回文重复相关转座酶。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票比 Metagenomi 更好</li>
<li>ETF 筛选器：用途和逐步指南</li>
<li>D-Wave 的欧洲扩张会继续推动反弹吗？</li>
<li>3 只杂货股票证明它们仍然是必需品</li>
<li>Navitas 在 NVIDIA 更新后飙升 78%：这次反弹可持续吗？</li>
<li>什么是便士股票？全面指南</li>
<li>现金消耗与谨慎资本：哪种 eVTOL 策略将获胜</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUdY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUdY"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Metagenomi 吗？</h2>
<p>在你考虑 Metagenomi 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Metagenomi 并不在名单上。</p>
<p>虽然 Metagenomi 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>Metagenomi, Inc.（纳斯达克代码：MGX）获得了五位分析师的 “适度买入” 共识推荐。平均一年目标价为 10.00 美元，其中一位分析师给予卖出评级，三位给予买入评级，一位给予强力买入评级。最近的机构投资包括先锋集团将其持股增加了 53.1%。股价上涨了 9.8%，达到 3.35 美元，市值为 1.2573 亿美元。Metagenomi 报告的季度每股收益为（0.54 美元），超出预期，收入为 851 万美元。分析师预测当前年的每股收益为-2.46 美元</p>

<p>Metagenomi, Inc. (NASDAQ:MGX - Get Free Report) has received an average recommendation of &#34;Moderate Buy&#34; from the five analysts that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $10.00.</p>
<div class="lb-trans"><p>Metagenomi, Inc.（纳斯达克代码：MGX - 获取免费报告）目前获得了五位分析师的平均推荐评级为 “适度买入”，MarketBeat 报道称。其中一位分析师给予该股票卖出评级，三位分析师给予买入评级，另一位分析师则给予强烈买入评级。在过去一年中，发布报告的券商对该股票的平均一年目标价为 10.00 美元。</p>
</div><p>Several research analysts have weighed in on the stock. HC Wainwright reiterated a &#34;buy&#34; rating and issued a $7.00 price objective on shares of Metagenomi in a research note on Tuesday, August 19th. Chardan Capital cut their price objective on Metagenomi from $12.00 to $11.00 and set a &#34;buy&#34; rating for the company in a report on Friday, August 15th. Zacks Research upgraded Metagenomi from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Friday. Wells Fargo &amp; Company dropped their target price on Metagenomi from $16.00 to $12.00 and set an &#34;overweight&#34; rating on the stock in a research report on Thursday, August 14th. Finally, Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Metagenomi in a report on Wednesday, October 8th.</p>
<div class="lb-trans"><p>几位研究分析师对该股票发表了看法。HC Wainwright 在 8 月 19 日的研究报告中重申了 “买入” 评级，并对 Metagenomi 的股票设定了 7.00 美元的目标价。Chardan Capital 将 Metagenomi 的目标价从 12.00 美元下调至 11.00 美元，并在 8 月 15 日的报告中给予该公司 “买入” 评级。Zacks Research 在周五的研究报告中将 Metagenomi 的评级从 “持有” 上调至 “强烈买入”。富国银行在 8 月 14 日的研究报告中将 Metagenomi 的目标价从 16.00 美元下调至 12.00 美元，并对该股票给予 “超配” 评级。最后，Weiss Ratings 在 10 月 8 日的报告中重申了对 Metagenomi 股票的 “卖出（d-）” 评级。</p>
</div><p><strong>Check Out Our Latest Analysis on MGX</strong></p>
<div class="lb-trans"><p><strong>查看我们对 MGX 的最新分析</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Large investors have recently modified their holdings of the company. Vanguard Personalized Indexing Management LLC lifted its stake in Metagenomi by 53.1% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 21,515 shares of the company's stock worth $32,000 after purchasing an additional 7,458 shares during the period. Virtu Financial LLC bought a new stake in Metagenomi in the first quarter valued at $43,000. Bank of New York Mellon Corp lifted its holdings in shares of Metagenomi by 39.6% during the first quarter. Bank of New York Mellon Corp now owns 50,387 shares of the company's stock valued at $69,000 after acquiring an additional 14,296 shares during the period. Bank of America Corp DE grew its holdings in shares of Metagenomi by 482.9% in the 4th quarter. Bank of America Corp DE now owns 21,113 shares of the company's stock worth $76,000 after purchasing an additional 17,491 shares during the last quarter. Finally, Nuveen LLC acquired a new stake in shares of Metagenomi during the 1st quarter worth about $86,000.</p>
<div class="lb-trans"><p>大型投资者最近调整了对该公司的持股。Vanguard Personalized Indexing Management LLC 在第二季度将其在 Metagenomi 的持股增加了 53.1%。Vanguard Personalized Indexing Management LLC 目前拥有 21,515 股该公司的股票，价值 32,000 美元，此前在此期间购买了 7,458 股。Virtu Financial LLC 在第一季度购买了价值 43,000 美元的 Metagenomi 新股份。纽约梅隆银行在第一季度将其在 Metagenomi 的持股增加了 39.6%。纽约梅隆银行目前拥有 50,387 股该公司的股票，价值 69,000 美元，此前在此期间又收购了 14,296 股。美国银行在第四季度将其在 Metagenomi 的持股增加了 482.9%。美国银行目前拥有 21,113 股该公司的股票，价值 76,000 美元，此前在上个季度又购买了 17,491 股。最后，Nuveen LLC 在第一季度收购了价值约 86,000 美元的 Metagenomi 新股份。</p>
</div><h2>Metagenomi Stock Up 9.8%</h2>
<div class="lb-trans"><h2>Metagenomi 股票上涨 9.8%</h2>
</div><p>NASDAQ:MGX opened at $3.35 on Tuesday. The stock has a fifty day simple moving average of $2.22 and a 200 day simple moving average of $1.91. The firm has a market capitalization of $125.73 million, a price-to-earnings ratio of -1.42 and a beta of 0.27. Metagenomi has a 1-year low of $1.23 and a 1-year high of $4.92.</p>
<div class="lb-trans"><p>纳斯达克：MGX 周二开盘价为 3.35 美元。该股票的 50 日简单移动平均为 2.22 美元，200 日简单移动平均为 1.91 美元。该公司的市值为 1.2573 亿美元，市盈率为-1.42，贝塔值为 0.27。Metagenomi 的一年低点为 1.23 美元，一年高点为 4.92 美元。</p>
</div><p>Metagenomi (NASDAQ:MGX - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.14. The company had revenue of $8.51 million during the quarter, compared to analysts' expectations of $7.72 million. Metagenomi had a negative net margin of 257.99% and a negative return on equity of 37.84%. Equities analysts predict that Metagenomi will post -2.46 earnings per share for the current year.</p>
<div class="lb-trans"><p>Metagenomi（纳斯达克：MGX - 获取免费报告）最近一次公布财报是在 8 月 12 日。该公司报告季度每股收益为（0.54 美元），超出市场共识预期的（0.68 美元）0.14 美元。该公司在该季度的收入为 851 万美元，而分析师预期为 772 万美元。Metagenomi 的净利润率为-257.99%，股本回报率为-37.84%。股票分析师预测 Metagenomi 本年度每股收益将为-2.46 美元。</p>
</div><h2>Metagenomi Company Profile</h2>
<div class="lb-trans"><h2>Metagenomi 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.</p>
<div class="lb-trans"><p>Metagenomi, Inc. 是一家基因治疗公司，专注于利用元基因组学衍生的基因组编辑工具箱为患者开发治疗方案。该公司的基因组编辑工具箱包括可编程核酸酶、碱基编辑器以及 RNA 和 DNA 介导的整合系统，如原始编辑系统和成簇规律间隔短回文重复相关转座酶。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Metagenomi</li>
<li>ETF Screener: Uses and Step-by-Step Guide</li>
<li>Will D-Wave's European Expansion Keep Fueling the Rally?</li>
<li>3 Grocery Stocks That Are Proving They Are Still Essential</li>
<li>Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable?</li>
<li>What is a penny stock? A comprehensive guide</li>
<li>Cash Burn vs. Cautious Capital: Which eVTOL Strategy Will Win</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Metagenomi 更好</li>
<li>ETF 筛选器：用途和逐步指南</li>
<li>D-Wave 的欧洲扩张会继续推动反弹吗？</li>
<li>3 只杂货股票证明它们仍然是必需品</li>
<li>Navitas 在 NVIDIA 更新后飙升 78%：这次反弹可持续吗？</li>
<li>什么是便士股票？全面指南</li>
<li>现金消耗与谨慎资本：哪种 eVTOL 策略将获胜</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUdY" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=MGX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Metagenomi Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Metagenomi 吗？</h2>
</div><p>Before you consider Metagenomi, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Metagenomi 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metagenomi wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Metagenomi 并不在名单上。</p>
</div><p>While Metagenomi currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Metagenomi 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Metagenomi, Inc.（NASDAQ:MGX）被分析师一致推荐为 “适度买入”